Safety Study of AMG 228 to Treat Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
Checked against the public recordLast updated Nov 8, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Amgen
- Interventions being studied
- Drug: AMG 228
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Subject must have a pathologically documented, definitively diagnosed, advanced solid tumor * Adequate hematological, renal, hepatic, and coagulation laboratory assessments Exclusion Criteria: * Active autoimmune disease, history of autoimmune disease * Treatment with immune modulators including * Use of warfarin, factor Xa inhibitors, or direct thrombin inhibitors * Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days * Major surgery within 28 days of study day 1
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Research SiteLa Jolla, California
- Research SiteNew Haven, Connecticut
- Research SiteNew York, New York
- Research SiteParkville, Victoria
- Research SiteLeuven
- Research SiteVillejuif
- Research SiteHeidelberg
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 8, 2022. Always confirm current availability with the study team.